AdaptHealth account plan
Medical equipment distribution and services
At a glance
AdaptHealth is a US home medical equipment and supplies provider: $3,244.9 million FY2025 revenue, about 10,900 employees, 4.8 million patients a year.
AdaptHealth Corp., headquartered in Conshohocken, Pennsylvania, delivers home medical equipment, medical supplies and related services to patients at home after hospital discharge or physician referral, billing Medicare, Medicaid and commercial payors. As of September 30, 2026 it served approximately 4.8 million patients annually through approximately 660 locations in 48 states. FY2025 net revenue was $3,244.9 million (down 0.5%), Adjusted EBITDA $616.7 million and the net loss attributable to AdaptHealth $70.8 million after a goodwill impairment. It had approximately 10,900 employees at December 31, 2025, plus about 4,400 outsourced full-time-equivalent staff in India and the Philippines; all operations are in the United States.
Business units
Sleep Health
42.5% of FY2025 net revenue ($1,378.1 million)CPAP and BiLevel equipment, supplies and services for obstructive sleep apnea patients, mostly PAP resupply. Census reached a record 1,730,000 at end-2025. In Q3 2026 net revenue rose 11.0% to $393.9 million on a large capitated contract, but Adjusted EBITDA fell 8.2% to $70.7 million on labor and product costs, including higher prices from a key supplier.
Respiratory Health
21.2% of FY2025 net revenue ($691.2 million)Oxygen and home mechanical ventilation equipment, supplies and chronic therapy services for COPD and chronic respiratory failure, mostly rented. Oxygen census was about 335,000 at end-2025. Q3 2026 net revenue rose 7.8% to $190.8 million and Adjusted EBITDA 9.7% to $56.2 million.
Wellness at Home
18.0% of FY2025 net revenue ($583.1 million)Hospital beds, wheelchairs, walkers, commodes and medical supplies for patients at home. FY2025 revenue fell 9.8% after the sale of incontinence and infusion businesses. Q3 2026 net revenue rose 14.5% to $161.0 million while Adjusted EBITDA fell 16.0% to $14.9 million.
Diabetes Health (being sold)
18.3% of FY2025 net revenue ($592.4 million)Continuous glucose monitors, insulin pumps and related services. After a $128.0 million goodwill impairment in Q4 2025, the business is being sold for $235.0 million in cash under a July 19, 2026 agreement, with closing expected in Q1 2027; it is reported as discontinued operations.
Strategic priorities
- Making the large capitated contract profitable
- The contract with Kaiser on the West Coast reached a margin of about 10% in Q3 2026 from -4% in Q2, exiting at a 14% run rate; the target is a 20% margin by Q4 2027, before any repricing.
- Focus on Sleep, Respiratory and Wellness at Home
- With the Diabetes Health sale, AdaptHealth becomes a three-segment business; about $60 million of overhead previously allocated to Diabetes Health has to be cut or absorbed.
- Deleveraging to 2.5x
- Net debt was $1.85 billion with total leverage of 3.05x after Q3 2026; the target is 2.5x, with a significant portion of the Diabetes Health proceeds going to debt reduction.
- Growing capitated and enterprise business
- An enterprise sales team signed four preferred-provider agreements with health systems, and two regional capitated agreements cover 72,000 exclusive lives.
- Technology and AI in workflows
- AI pilots for sleep order intake and PAP self-scheduling are being expanded in 2026; myAPP has more than 615,000 registered users and the AI mask-fitting tool has completed more than 12,600 scans.
Latest results
In Q3 2026 net revenue from continuing operations was $745.6 million, up 10.9% (organic +12.8%), with capitated revenue rising to $110.3 million, 14.8% of net revenue. Adjusted EBITDA was $141.9 million (19.0% margin vs 21.7%), $11.2 million above the guidance midpoint. The net loss attributable to AdaptHealth was $168.2 million after a $184.8 million goodwill impairment on Respiratory Health and Wellness at Home. Nine-month free cash flow fell to $2.6 million from $140.1 million on equipment bought for capitated contracts. 2026 guidance is net revenue of $2.88-$2.90 billion, Adjusted EBITDA of $510-$525 million and free cash flow of $55-$80 million, down from the February guidance of $3.44-$3.51 billion revenue.
Investments and deals
- Diabetes Health divestment
- Sale for $235.0 million in cash agreed July 19, 2026; the Hart-Scott-Rodino waiting period has expired and closing is expected in Q1 2027.
- Capitated-contract asset purchases
- Assets bought from two previous providers in four transactions for $127.3 million in cash in 2026, to transition patients under newly awarded capitated contracts.
- 2026 refinancing
- A 2026 Credit Agreement (April 10, 2026) of a $325.0 million term loan, a $325.0 million delayed draw term loan and a $450.0 million revolver; the $325.0 million 6.125% Senior Notes were redeemed on August 3, 2026.
- Cost-reduction plan
- A June 2026 plan with headcount cuts and the wind-down of an immaterial business cost $6.1 million and targets about $26.8 million of annual savings.
- Portfolio pruning in 2025
- Incontinence and infusion businesses were sold in 2025 (gross proceeds $69.1 million and $53.5 million); the eCommerce subsidiary was contributed to a joint venture in July 2026.
Challenges and risks
- Capitated contract costs
- Utilization was higher than expected from day one and the cost to serve at the partner's hospitals was not assumed in pricing; capex is running at 14.2% of net revenue.
- Supplier pricing and concentration
- A manufacturer terminated its contract on June 30, 2026 with an immediate price increase estimated at about $30 million of second-half Adjusted EBITDA, and Medline is removing its beds from the market; AdaptHealth buys most categories from two to three suppliers.
- Reimbursement and regulation
- Dependence on Medicare, Medicaid and private payors, the resumption of the DMEPOS Competitive Bidding Program (contracts in effect no later than January 1, 2028) and two open False Claims Act civil investigative demands.
- Cyber security
- A social-engineering attack disclosed on July 2, 2026 led to exfiltration of patient information and a stored insurance-billing password file.
- Stranded cost and margin pressure
- About $30 million of overhead from Diabetes Health is "true stranded cost"; the nine-month 2026 Adjusted EBITDA margin was 17.5% vs 20.0%.
What leadership says
“we are a focused Sleep, Respiratory, and Wellness at Home business, where growth and margins are more attractive.”
“We have been provided assurances that pricing adjustments are coming”
“Our new capitated contract is a massive undertaking, the largest service transition in the HME industry's history.”
Where a supplier can help
- Labor efficiency on the capitated contract
- Tied to the 20% margin target on the large capitated contract: workforce scheduling, logistics and automation tools that lower cost to serve match the tighter labor model the company is running.
- Alternative equipment suppliers
- Tied to the manufacturer price increase and Medline's bed exit: suppliers of PAP devices, beds and other HME can offer diversification the company has already begun.
- Security and identity protection
- Tied to the 2026 social-engineering cyber incident: identity, access and security awareness services address the attack vector described.
- AI and digital patient workflows
- Tied to the AI order-intake and self-scheduling rollout: conversational AI, intake automation and patient app vendors fit a stated 2026 expansion.
- Overhead reduction after the Diabetes sale
- Tied to the $60 million of overhead to cut or absorb: outsourcing, back-office and IT consolidation offers can help remove stranded cost.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like AdaptHealth?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- AdaptHealth Corp. Annual Report on Form 10-K for fiscal year 2025
- AdaptHealth is a US healthcare-at-home provider of home medical equipment (HME), medical supplies and related services: about 4.3 million patients served annually in all 50 states from about 640 locations in 48 states, roughly 10,900 employees plus about 4,400 outsourced full-time-equivalent staff (India, Philippines) at December 31, 2025.
- FY2025 net revenue was $3,244.9 million (down 0.5%; organic +1.7%, acquisitions +0.6%, dispositions -2.8%); Adjusted EBITDA $616.7 million (19.0% margin vs 21.1% in 2024); net loss attributable to AdaptHealth of $70.8 million after a $128.0 million goodwill impairment on Diabetes Health.
- Four reportable segments in FY2025: Sleep Health $1,378.1 million (42.5% of revenue), Respiratory Health $691.2 million (21.2%), Diabetes Health $592.4 million (18.3%), Wellness at Home $583.1 million (18.0%).
- Revenue model: resupply and one-time sales about 63% of net revenue, fixed monthly equipment rentals about 33%, at-risk capitation (per member per month) about 4.0%.
- Portfolio pruning: incontinence and infusion businesses sold in 2025 (gross proceeds $69.1 million and $53.5 million), pre-tax gain $32.6 million; five HME acquisitions for $42.8 million in cash.
- Cash and debt: operating cash flow $601.8 million, patient equipment and fixed asset purchases $382.4 million, free cash flow $219.4 million; $218.8 million of voluntary term loan repayments; $1,435.0 million of senior notes outstanding.
- Risks: Medicare/Medicaid reimbursement and audits, resumption of the DMEPOS Competitive Bidding Program (bid window late summer/early fall 2026, contracts in effect no later than January 1, 2028), One Big Beautiful Bill Act Medicaid changes, two open False Claims Act civil investigative demands (PAP humidifiers, respiratory devices), supplier concentration, GLP-1 drugs, cyber risk.
- Organisation: CEO Suzanne Foster, CFO Jason Clemens (signatories); each segment has a general manager reporting to the Chief Operating Officer, with centralised revenue cycle, purchasing, payor contracting, M&A, IT and resupply.
- AdaptHealth Corp. Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)
- Q3 2026 (quarter to September 30, 2026) net revenue from continuing operations was $745.6 million, up 10.9%; nine-month revenue $2,165.8 million, up 9.7%.
- Diabetes Health is being sold for $235.0 million in cash, agreed July 19, 2026, expected to close in Q1 2027; it is now reported as discontinued operations, leaving three segments: Sleep Health, Respiratory Health and Wellness at Home.
- Capitated revenue rose to $110.3 million, 14.8% of Q3 net revenue (4.7% a year earlier), driven by a capitated contract entered into in Q3 2025.
- Q3 Adjusted EBITDA $141.9 million (19.0% margin vs 21.7%); net loss attributable to AdaptHealth $168.2 million after $184.8 million of goodwill impairment on Respiratory Health and Wellness at Home ($329.0 million over nine months).
- Nine-month free cash flow was $2.6 million (vs $140.1 million) as equipment purchases of $393.0 million and $127.3 million of asset acquisitions supported capitated contracts.
- Refinancing: a new 2026 Credit Agreement (April 10, 2026) of $325.0 million term loan, $325.0 million delayed draw term loan and a $450.0 million revolver; the 6.125% Senior Notes ($325.0 million) were redeemed in August 2026.
- A June 2026 cost-reduction plan (headcount cuts, wind-down of an immaterial business) cost $6.1 million and targets about $26.8 million of annual savings.
- A social-engineering cyber incident disclosed on July 2, 2026 led to exfiltration of patient information and a stored insurance-billing password file; the company does not expect a material financial impact.
- AdaptHealth Q3 2026 earnings call transcript
- Q3 2026 call (November 3, 2026), CEO Suzanne Foster and new CFO Harriss Currie (joined September 2026): net revenue $745.6 million (+10.9%, organic +12.8%), Adjusted EBITDA $141.9 million, above the guidance midpoint by $11.2 million.
- The largest capitated contract (Kaiser on the West Coast, an integrated delivery network in eight markets) swung to a margin of about 10% in Q3 from -4% in Q2, exiting at a 14% run rate; target of a 20% margin by Q4 2027, before any repricing now being negotiated.
- Headcount dedicated to the contract is down more than 12% since Q2; group headcount 10,995, down 337 since the end of June.
- A large manufacturer (ResMed, named by an analyst) terminated its contract on June 30 with an immediate price increase, estimated at about $30 million of H2 Adjusted EBITDA; a rebate structure recovered $8 million in Q3.
- 2026 guidance raised to net revenue of $2.88-$2.90 billion and Adjusted EBITDA of $510-$525 million; free cash flow lowered to $55-$80 million; net debt $1.85 billion, leverage 3.05x, target 2.5x with Diabetes sale proceeds going largely to debt reduction.
- Commercial: four preferred-provider agreements with health systems via a new enterprise sales team; two regional capitated deals covering 72,000 lives (about $7-8 million of annual revenue); myAPP above 615,000 users; AI mask-fitting tool at 12,600 scans with about 94% converting to orders.
- Risks: Medline is pulling its beds from the market (beds are low single digits of revenue); PCS low-margin channels being wound down; $60 million of overhead formerly allocated to Diabetes Health, half of which is stranded cost.
- AdaptHealth Q4 and full-year 2025 earnings call transcript
- Q4 2025 call (February 24, 2026), CEO Suzanne Foster and CFO Jason Clemens: FY2025 net revenue $3,245 million, organic growth 1.7%; Adjusted EBITDA $616.7 million (19% margin), hit by a $14.5 million legal settlement and about $10 million of accelerated onboarding costs for the new capitated contract.
- Foster called the new capitated contract "the largest service transition in the HME industry's history": over 10 million patients when fully live, about 1,200 dedicated employees across 30 locations; three Mid-Atlantic states (about 50,000 members) went live in December, the West Coast on February 1.
- Patient census records: Sleep Health 1,730,000 (+4%), with Q4 new starts of about 130,600 (+6%); oxygen census about 335,000; CGM census flat at about 153,000 because of payer mix.
- Operations: sleep referral-to-setup time cut to nine days from 23 a year earlier; centralised order intake; AI pilots for sleep order intake and PAP self-scheduling to be expanded in 2026; myAPP above 327,000 users.
- Balance sheet: $250 million of debt reduction in 2025, net debt $1,694 million, net leverage 2.75x (target 2.5x), S&P and Moody's upgrades, free cash flow $219.4 million.
- Initial 2026 guidance: net revenue $3.44-$3.51 billion, Adjusted EBITDA $680-$730 million, free cash flow $175-$225 million, with 5%-6% growth from the new capitated agreement (later revised down in August 2026).
- CMS excluded core sleep and respiratory products from the next competitive bidding round; a Hawaii HME provider was acquired (48 states) and $47.6 million of provider assets bought after year-end.
Questions about AdaptHealth
What does AdaptHealth do?
AdaptHealth provides home medical equipment, medical supplies and related services such as CPAP, oxygen and hospital beds to patients at home across the United States.
What was AdaptHealth's revenue in 2025?
FY2025 net revenue was $3,244.9 million, down 0.5%, with Adjusted EBITDA of $616.7 million.
How many employees does AdaptHealth have?
About 10,900 employees at December 31, 2025, plus about 4,400 outsourced full-time-equivalent staff; group headcount was 10,995 after Q3 2026 according to the earnings call.
Who leads AdaptHealth?
Suzanne Foster is Chief Executive Officer; Harriss Currie became CFO in September 2026, succeeding Jason Clemens.
Is AdaptHealth selling its diabetes business?
Yes. Diabetes Health is being sold for $235.0 million in cash, with closing expected in Q1 2027.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)